These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8463291)

  • 1. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo.
    Gibbs JB; Pompliano DL; Mosser SD; Rands E; Lingham RB; Singh SB; Scolnick EM; Kohl NE; Oliff A
    J Biol Chem; 1993 Apr; 268(11):7617-20. PubMed ID: 8463291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase.
    Dufresne C; Wilson KE; Singh SB; Zink DL; Bergstrom JD; Rew D; Polishook JD; Meinz M; Huang L; Silverman KC
    J Nat Prod; 1993 Nov; 56(11):1923-9. PubMed ID: 8289063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oreganic acid, a potent inhibitor of ras farnesyl-protein transferase.
    Silverman KC; Jayasuriya H; Cascales C; Vilella D; Bills GF; Jenkins RG; Singh SB; Lingham RB
    Biochem Biophys Res Commun; 1997 Mar; 232(2):478-81. PubMed ID: 9125205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein farnesyltransferase: measurement of enzymatic activity in 96-well format using TopCount microplate scintillation counting technology.
    Harwood HJ
    Anal Biochem; 1995 Apr; 226(2):268-78. PubMed ID: 7793628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chaetomella acutiseta produces chaetomellic acids A and B which are reversible inhibitors of farnesyl-protein transferase.
    Lingham RB; Silverman KC; Bills GF; Cascales C; Sanchez M; Jenkins RG; Gartner SE; Martin I; Diez MT; Peláez F
    Appl Microbiol Biotechnol; 1993 Nov; 40(2-3):370-4. PubMed ID: 7764394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts.
    Ura H; Obara T; Shudo R; Itoh A; Tanno S; Fujii T; Nishino N; Kohgo Y
    Mol Carcinog; 1998 Feb; 21(2):93-9. PubMed ID: 9496909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
    J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
    Sepp-Lorenzino L; Ma Z; Rands E; Kohl NE; Gibbs JB; Oliff A; Rosen N
    Cancer Res; 1995 Nov; 55(22):5302-9. PubMed ID: 7585592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids.
    Hohl RJ; Lewis KA; Cermak DM; Wiemer DF
    Lipids; 1998 Jan; 33(1):39-46. PubMed ID: 9470172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Farnesylamine: an inhibitor of farnesylation and growth of ras-transformed cells.
    Kothapalli R; Guthrie N; Chambers AF; Carroll KK
    Lipids; 1993 Nov; 28(11):969-73. PubMed ID: 8277827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of farnesyl-protein-transferase in neuroblastoma cells by alpha-hydroxyfarnesylphosphonate.
    Girgert R; Hohnecker A; Wittrock J; Schweizer P
    Anticancer Res; 1999; 19(4B):2959-62. PubMed ID: 10652579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells.
    Bishop WR; Bond R; Petrin J; Wang L; Patton R; Doll R; Njoroge G; Catino J; Schwartz J; Windsor W
    J Biol Chem; 1995 Dec; 270(51):30611-8. PubMed ID: 8530497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient syntheses, human and yeast farnesyl-protein transferase inhibitory activities of chaetomellic acids and analogues.
    Singh SB; Jayasuriya H; Silverman KC; Bonfiglio CA; Williamson JM; Lingham RB
    Bioorg Med Chem; 2000 Mar; 8(3):571-80. PubMed ID: 10732974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor.
    Kohl NE; Mosser SD; deSolms SJ; Giuliani EA; Pompliano DL; Graham SL; Smith RL; Scolnick EM; Oliff A; Gibbs JB
    Science; 1993 Jun; 260(5116):1934-7. PubMed ID: 8316833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein farnesyltransferase inhibitors interfere with farnesyl diphosphate binding by rubber transferase.
    Mau CJ; Garneau S; Scholte AA; Van Fleet JE; Vederas JC; Cornish K
    Eur J Biochem; 2003 Oct; 270(19):3939-45. PubMed ID: 14511375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
    Yonemoto M; Satoh T; Arakawa H; Suzuki-Takahashi I; Monden Y; Kodera T; Tanaka K; Aoyama T; Iwasawa Y; Kamei T; Nishimura S; Tomimoto K
    Mol Pharmacol; 1998 Jul; 54(1):1-7. PubMed ID: 9658183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin.
    Chen X; Hasuma T; Yano Y; Yoshimata T; Morishima Y; Wang Y; Otani S
    Anticancer Res; 1997; 17(4A):2555-64. PubMed ID: 9252680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.
    Gibbs JB; Oliff A
    Annu Rev Pharmacol Toxicol; 1997; 37():143-66. PubMed ID: 9131250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin stimulates mitogen-activated protein kinase by a Ras-independent pathway in 3T3-L1 adipocytes.
    Carel K; Kummer JL; Schubert C; Leitner W; Heidenreich KA; Draznin B
    J Biol Chem; 1996 Nov; 271(48):30625-30. PubMed ID: 8940037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.